The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a ...

Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL.

Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...

Company AnnouncementTopline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated ...

Genmab ( (GMAB)) has provided an update. Genmab A/S, an international biotechnology company specializing in next-generation antibody medicines for cancer, develops bispecific antibodies, antibody–drug ...

View Genmab A/S Sponsored ADR GMAB stock quote prices, financial information, real-time forecasts, and company news from CNN.

Genmab A/S (NASDAQ:GMAB) is one of the 15 large cap stocks under $30 with huge upside potential. As of the March 23 closing, consensus sentiment for Genmab A/S (NASDAQ:GMAB) remained strongly bullish.

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As the oncology landscape continues to evolve, companies are increasingly evaluated on their ability to translate scientific expertise into sustained patient impact. For Genmab, long recognized for ...